Art is Her Best Friend

Yvonne is living her dream. She is an artist, dedicated to raising awareness and funds for vision research.

Become a Community Fundraiser

Community events are a fun way for you to join the fight against blindness and fund sight saving research. Host a fundraiser in your community today!

Out-pacing vision loss

Cycle for Sight founder and co-chair, Michael Ovens, will cycle any distance or run any length to help support sight-saving research.

Meet Molly Burke, FFB Youth Ambassador

Youth Ambassador

Molly Burke is a youth ambassador for the Foundation Fighting Blindness, educating the public about living with blindness while delivering a message of hope to those living with vision impairment.

Meet Norma Bastidas, mom on a mission

Mom on a Mission

Norma is the second person in history to run 7 of the planet's most unforgiving environments on 7 continents in 1 year in support of vision research. Read her about incredible journey.

Meet Dale Turner, proof that research does work

Miracles do happen

Dale Turner is the first Canadian to receive an experimental treatment and have some sight restored by gene therapy. Dale is proof that investing in research works.

Canadian Scientists Show “Proof of Principle” for LCA 12 Gene Therapy

June 11, 2013 – Research led by Dr. Robert Molday at the University of British Columbia has shown that gene therapy designed to target the RD3 gene can protect light-sensing photoreceptors and restore visual function in mice. In humans, mutations in the RD3 gene interfere with the production of an essential protein in the eye and cause Leber congenital amaurosis type 12.  This research was made possible thanks to funding from the Foundation Fighting Blindness and the Canadian Institutes of Health Research.

Leber congenital amaurosis (LCA) is a genetic condition that causes severe loss of vision at birth or early in childhood. Eighteen genes which cause LCA have now been identified. By studying these genes, Dr. Molday and other scientists have begun to develop therapies that can slow vision loss and even restore some sight.

In this research, Dr. Molday and his colleagues uses a virus called AAV8 to carry a new RD3 gene into the photoreceptor of mice born without the RD3 gene. (To learn more about this process, see our short video on gene therapy.) They showed that the new gene could function inside the photoreceptor, preventing cell death and restoring visual function to both rod and cone photoreceptors in mice with some types of RD3 mutations.  This type of gene replacement therapy has already been adapted to deliver another gene associated with LCA2; human trials of that therapy are ongoing. For more detailed information, see our gene therapy fact sheet.

Dr. Molday currently leads a team of scientists funded by the Foundation Fighting Blindness and the Canadian Institutes of Health Research working to develop gene therapies for inherited retinal degenerative diseases.

This research was published in Human Molecular Genetics, June 4, 2013.

You can help – support us today!

Privacy Policy | Accessibility Policy